Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)

Ibrutinib is an inhibitor of Bruton's tyrosine kinase that has been approved for the treatment of patients with chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom's macroglobulinemia and is connected with toxicities. To minimize its toxicities, we linked ibrutinib to a cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Faust, Andreas, Bäumer, Nicole, Schlütermann, Alina, Becht, Manuel, Greune, Lilo, Geyer, Christiane, Rüter, Christian, Margeta, Renato, Wittmann, Lisa, Dersch, Petra, Lenz, Georg, Berdel, Wolfgang E., Bäumer, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299256/
https://www.ncbi.nlm.nih.gov/pubmed/34725904
http://dx.doi.org/10.1002/anie.202109769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299256/
https://www.ncbi.nlm.nih.gov/pubmed/34725904
http://dx.doi.org/10.1002/anie.202109769

Ejemplares similares